MedTrace Logo

JomCare Study - A Harm Reduction Study

NCT06794840 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 482

Last updated 2026-02-23

No results posted yet for this study

Summary

Chemsex, the use of psychoactive drugs before or during sexual activity, is a growing public health concern associated with striking increases in HIV, particularly among men who have sex with men (MSM). This study proposes to optimize an app-based just-in-time adaptive intervention, called JomCare, which aims to reduce chemsex risk by delivering tailored support when a person is most likely to be vulnerable to chemsex risk behaviors and receptive to intervention, with the purpose of reducing risk and averting new HIV infections.

Conditions

  • HIV
  • Substance Abuse Disorder

Interventions

BEHAVIORAL

JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) for chemsex-related harm reduction.

JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) that uses an EMA-based machine learning (ML) algorithm to anticipate chemsex risk and deliver appropriate chemsex-related harm reduction and HIV prevention services when the risk is detected.

Sponsors & Collaborators

  • University of Malaya

    collaborator OTHER

  • Yale University

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Michigan

    collaborator OTHER

  • University of Texas at Tyler

    collaborator OTHER

  • Ohio State University

    collaborator OTHER

  • University of Connecticut

    lead OTHER

Principal Investigators

  • Roman Shrestha, PhD · University of Connecticut

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2029-05-30
Completion
2029-05-30

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06794840 on ClinicalTrials.gov